Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.880
-0.010 (-0.53%)
At close: Mar 6, 2026, 4:00 PM EST
1.900
+0.020 (1.06%)
After-hours: Mar 6, 2026, 6:42 PM EST

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Biotechnology
260.50K123.44K3.10M698.47K1.12M
Biotechnology Growth
111.03%-96.02%343.92%-37.79%-72.22%
Total
260.50K123.44K3.10M698.47K1.12M
Total Growth
111.03%-96.02%343.92%-37.79%-72.22%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
United States
260.50K123.44K3.10M698.47K1.12M
United States Growth
111.03%-96.02%343.92%-37.79%-72.22%
Total
260.50K123.44K3.10M698.47K1.12M
Total Growth
111.03%-96.02%343.92%-37.79%-72.22%
Source: S&P Global Market Intelligence.